Future of gene-based medicines
EVis Bioscience is an ETH spin-off developing a next-generation non-viral vector for targeted gene therapy.
A pioneer approach to treating genetic disorders
We develop innovative gene delivery systems for targeted and personalized medicine.
This includes extracellular vesicles, synthetic lipid nanoparticles, and their hybrids.
Gene delivery
Novel opportunities to deliver small and large nucleic acids using extracellular vesicles for targeted and personalized medicine
Internal pipeline
Development of gene therapy-based candidates for rare genetic diseases
Vehicle sublicenses
We offer our proprietary hybrid technology to pharmaceutical partners to support the development of targeted gene-based therapies
Service
We provide services and facilities to research labs focused on the delivery of nucleic acids using extracellular vesicles
RNA loading kit: NanoVector
We offer our chemical kit to load your EVs with small and large RNAs, protecting the EV structure and biological activity
Fluorescent kit
We offer our fluorescent kit to track EVs in tube and in vitro, protecting the EV structure and biological activity
Latest posts
Supported by
Partner with Us
We develop our drug product and support pharmaceutical partners by providing our hybrid technology to enable innovative gene therapies for patients.
JOIN THE INNOVATION
We develop our drug product and support pharmaceutical partners by providing our hybrid technology to enable innovative gene therapies for patients.